Antiviral Susceptibility of Avian and Swine Influenza Virus of the N1 Neuraminidase Subtype (cid:1)

Influenza viruses of the N1 neuraminidase (NA) subtype affecting both animals and humans caused the 2009 pandemic. Anti-influenza virus NA inhibitors are crucial early in a pandemic, when specific influenza vaccines are unavailable. Thus, it is urgent to confirm the antiviral susceptibility of the avian viruses, a potential source of a pandemic virus. We evaluated the NA inhibitor susceptibilities of viruses of the N1 subtype isolated from wild waterbirds, swine, and humans. Most avian viruses were highly or moderately susceptible to oseltamivir (50% inhibitory concentration [IC 50 ], <5.1 to 50 nM). Of 91 avian isolates, 7 (7.7%) had reduced susceptibility (IC 50 , >50 nM) but were sensitive to the NA inhibitors zanamivir and peramivir. Oseltamivir susceptibility ranged more widely among the waterbird viruses (IC 50 , 0.5 to 154.43 nM) than among swine and human viruses (IC 50 , 0.33 to 2.56 nM). Swine viruses were sensitive to oseltamivir, compared to human seasonal H1N1 isolated before 2007 (mean IC 50 , 1.4 nM). Avian viruses from 2007 to 2008 were sensitive to oseltamivir, in contrast to the emergence of resistant H1N1 in humans. Susceptibility remained high to moderate over time among influenza viruses. Sequence analysis of the outliers did not detect molecular markers of drug-resistance (e.g., H275Y NA mutation [N1 numbering]) but revealed mutations outside the NA active site. In particular, V267I, N307D, and V321I residue changes were found, and structural analyses suggest that these mutations distort hydrophobic pockets and affect residues in the NA active site. We determined that natural oseltamivir resistance among swine and wild waterbirds is rare. Minor naturally occurring variants in NA can affect antiviral susceptibility.

[1]  J. Stockman H1N1 2009 influenza virus infection during pregnancy in the USA , 2011 .

[2]  R. Webster,et al.  Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. , 2010, The Journal of general virology.

[3]  Hiroaki Tanaka,et al.  Oseltamivir Carboxylate, the Active Metabolite of Oseltamivir Phosphate (Tamiflu), Detected in Sewage Discharge and River Water in Japan , 2009, Environmental health perspectives.

[4]  P. Collins,et al.  Structural basis for oseltamivir resistance of influenza viruses. , 2009, Vaccine.

[5]  W. Wu Control of avian influenza A H5N1 in China. , 2009, The Lancet. Infectious diseases.

[6]  M. Peacey,et al.  Pandemic influenza A(H1N1)v viruses currently circulating in New Zealand are sensitive to oseltamivir. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  Ron A M Fouchier,et al.  Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans , 2009, Science.

[8]  Yi Guan,et al.  Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  David Smith,et al.  Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. , 2009, Antiviral research.

[10]  J. Fick,et al.  Detection of the Antiviral Drug Oseltamivir in Aquatic Environments , 2009, PloS one.

[11]  Gavin J. D. Smith,et al.  Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic , 2009, Nature.

[12]  Jon Cohen Swine flu outbreak. New details on virus's promiscuous past. , 2009, Science.

[13]  J. Taubenberger,et al.  Pandemic influenza--including a risk assessment of H5N1. , 2009, Revue scientifique et technique.

[14]  J. van de Kassteele,et al.  Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season , 2009, Emerging infectious diseases.

[15]  Lynnette Brammer,et al.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. , 2009, JAMA.

[16]  A. Lackenby,et al.  Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007–08 , 2009, Emerging infectious diseases.

[17]  Makoto Ujike,et al.  Isolation of oseltamivir-resistant influenza A/H1N1 virus of different origins in Yokohama City, Japan, during the 2007-2008 influenza season. , 2009, Japanese journal of infectious diseases.

[18]  Tanja Popovic,et al.  Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[19]  A. Osterhaus,et al.  Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. , 2008, Antiviral research.

[20]  Larisa V. Gubareva,et al.  Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008 , 2008, Antimicrobial Agents and Chemotherapy.

[21]  S. van der Werf,et al.  Enzymatic Properties of the Neuraminidase of Seasonal H1N1 Influenza Viruses Provide Insights for the Emergence of Natural Resistance to Oseltamivir , 2008, PLoS pathogens.

[22]  G. Boivin,et al.  Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. , 2008, Antiviral research.

[23]  M. Zambon,et al.  Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[24]  Mats Tysklind,et al.  Antiviral Oseltamivir Is not Removed or Degraded in Normal Sewage Water Treatment: Implications for Development of Resistance by Influenza A Virus , 2007, PloS one.

[25]  R. Webster,et al.  Evolution of influenza A viruses in wild birds , 2007 .

[26]  R. Webster,et al.  H5N1 influenza--continuing evolution and spread. , 2006, The New England journal of medicine.

[27]  I. Stephenson,et al.  Use of neuraminidase inhibitors to combat pandemic influenza. , 2006, The Journal of antimicrobial chemotherapy.

[28]  R. Webster,et al.  Importance of Neuraminidase Active-Site Residues to the Neuraminidase Inhibitor Resistance of Influenza Viruses , 2006, Journal of Virology.

[29]  Catherine Macken,et al.  Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use , 2006, Antimicrobial Agents and Chemotherapy.

[30]  P. Agarwal Enzymes: An integrated view of structure, dynamics and function , 2006, Microbial cell factories.

[31]  A. Moscona,et al.  Oseltamivir resistance--disabling our influenza defenses. , 2005, The New England journal of medicine.

[32]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[33]  Jeffery K. Taubenberger,et al.  Characterization of the 1918 influenza virus polymerase genes , 2005, Nature.

[34]  A. Osterhaus,et al.  Mallards and Highly Pathogenic Avian Influenza Ancestral Viruses, Northern Europe , 2005, Emerging infectious diseases.

[35]  B. Lina,et al.  Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. , 2005, Antiviral research.

[36]  Y Li,et al.  The evolution of H5N1 influenza viruses in ducks in southern China. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Y. Guan,et al.  Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia , 2004, Nature.

[38]  F. Hayden,et al.  Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir , 2003, Antimicrobial Agents and Chemotherapy.

[39]  I. Barr,et al.  Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. , 2003, Communicable diseases intelligence quarterly report.

[40]  Larisa V. Gubareva,et al.  Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants , 2001, Antimicrobial Agents and Chemotherapy.

[41]  R. Webster,et al.  Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses , 2001, Antimicrobial Agents and Chemotherapy.

[42]  R. Webster,et al.  Influenza: an emerging disease. , 1998, Emerging infectious diseases.

[43]  N. Bovin,et al.  Postreassortment changes in influenza A virus hemagglutinin restoring HA-NA functional match. , 1998, Virology.

[44]  R. Webster,et al.  A pandemic warning? , 1997, Nature.

[45]  R. Webster,et al.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en , 1997, Journal of virology.

[46]  M. Potier,et al.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. , 1979, Analytical biochemistry.

[47]  C. Dolea,et al.  World Health Organization , 1949, International Organization.